Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors. 2012

Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
Celgene Corporation, San Diego, 4550 Towne Centre Ct, San Diego, CA 92121, United States. gkpackardca@gmail.com

The serine/threonine specific protein kinase B-Raf is part of the MAPK pathway and is an interesting oncology target. We have identified thieno[2,3-d]pyrimidines as a core scaffold of small molecule B-Raf inhibitors. The SAR of analogs in this series will be described.

UI MeSH Term Description Entries
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014508 Urea A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. Basodexan,Carbamide,Carmol
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D048493 Proto-Oncogene Proteins B-raf A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2. B-raf Kinase,BRAF Kinase,B-raf Kinases,BRAF Kinases,Proto-Oncogene Protein B-raf,B raf Kinase,B raf Kinases,B-raf, Proto-Oncogene Protein,B-raf, Proto-Oncogene Proteins,Kinase, B-raf,Kinase, BRAF,Protein B-raf, Proto-Oncogene,Proteins B-raf, Proto-Oncogene,Proto Oncogene Protein B raf,Proto Oncogene Proteins B raf
D054703 Cyclic Nucleotide Phosphodiesterases, Type 4 A cyclic nucleotide phosphodiesterase subfamily that is found predominantly in inflammatory cells and may play a role in the regulation of CELL-MEDIATED IMMUNITY. The enzyme family includes over twenty different variants that occur due to multiple ALTERNATIVE SPLICING of the mRNA of at least four different genes. Cyclic Nucleotide Phosphodiesterase PDE4 Family,Cyclic Nucleotide Phosphodiesterases, Type 4A,Cyclic Nucleotide Phosphodiesterases, Type 4A5,Cyclic Nucleotide Phosphodiesterases, Type 4B,Cyclic Nucleotide Phosphodiesterases, Type 4C,Cyclic Nucleotide Phosphodiesterases, Type 4D,Cyclic Nucleotide Phosphodiesterases, Type 4D3,PDE4 Phosphodiesterases,PDE4D3 Phosphodiesterase,Phosphodiesterase 4,Phosphodiesterase 4A,Phosphodiesterase 4B,Phosphodiesterase 4C,Phosphodiesterase 4D,Phosphodiesterase IV,Phosphodiesterase-4,Type 4 Cyclic Nucleotide Phosphodiesterase,cAMP-Specific Phosphodiesterase 4A5,Phosphodiesterase 4A5, cAMP-Specific,Phosphodiesterase, PDE4D3,Phosphodiesterases, PDE4,cAMP Specific Phosphodiesterase 4A5

Related Publications

Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
July 2023, Future medicinal chemistry,
Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
January 1979, Archiv der Pharmazie,
Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
September 2019, mSphere,
Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
August 2010, Bioorganic & medicinal chemistry letters,
Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
November 2008, Die Pharmazie,
Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
May 2013, Bioorganic & medicinal chemistry letters,
Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
March 1973, Journal of medicinal chemistry,
Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
January 2017, Current medicinal chemistry,
Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
December 2009, Bioorganic & medicinal chemistry letters,
Garrick K Packard, and Patrick Papa, and Jennifer R Riggs, and Paul Erdman, and Lida Tehrani, and Dale Robinson, and Roy Harris, and Graziella Shevlin, and Sophie Perrin-Ninkovic, and Robert Hilgraf, and Margaret A McCarrick, and Tam Tran, and Yuedi Fleming, and April Bai, and Samantha Richardson, and Jason Katz, and Yang Tang, and Jim Leisten, and Mehran Moghaddam, and Brian Cathers, and Dan Zhu, and Steven Sakata
September 2008, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!